Autolus Therapeutics (AUTL) Competitors $2.15 -0.09 (-4.02%) As of 06/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AUTL vs. DNLI, CGON, VERA, GMTX, IMCR, GLPG, AGIO, TWST, IDYA, and TARSShould you be buying Autolus Therapeutics stock or one of its competitors? The main competitors of Autolus Therapeutics include Denali Therapeutics (DNLI), CG Oncology (CGON), Vera Therapeutics (VERA), Gemini Therapeutics (GMTX), Immunocore (IMCR), Galapagos (GLPG), Agios Pharmaceuticals (AGIO), Twist Bioscience (TWST), IDEAYA Biosciences (IDYA), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "pharmaceutical products" industry. Autolus Therapeutics vs. Its Competitors Denali Therapeutics CG Oncology Vera Therapeutics Gemini Therapeutics Immunocore Galapagos Agios Pharmaceuticals Twist Bioscience IDEAYA Biosciences Tarsus Pharmaceuticals Denali Therapeutics (NASDAQ:DNLI) and Autolus Therapeutics (NASDAQ:AUTL) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, profitability, institutional ownership, valuation, risk, dividends and media sentiment. Does the media favor DNLI or AUTL? In the previous week, Autolus Therapeutics had 1 more articles in the media than Denali Therapeutics. MarketBeat recorded 7 mentions for Autolus Therapeutics and 6 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.41 beat Autolus Therapeutics' score of 0.62 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Autolus Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, DNLI or AUTL? Denali Therapeutics has higher revenue and earnings than Autolus Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDenali Therapeutics$330.53M6.56-$145.22M-$2.67-5.59Autolus Therapeutics$9.01M63.50-$208.38M-$0.88-2.44 Is DNLI or AUTL more profitable? Denali Therapeutics' return on equity of -32.94% beat Autolus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Denali TherapeuticsN/A -32.94% -30.04% Autolus Therapeutics N/A -63.65%-36.54% Do insiders & institutionals have more ownership in DNLI or AUTL? 92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk and volatility, DNLI or AUTL? Denali Therapeutics has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. Does the MarketBeat Community believe in DNLI or AUTL? Denali Therapeutics received 240 more outperform votes than Autolus Therapeutics when rated by MarketBeat users. Likewise, 68.76% of users gave Denali Therapeutics an outperform vote while only 68.34% of users gave Autolus Therapeutics an outperform vote. CompanyUnderperformOutperformDenali TherapeuticsOutperform Votes47168.76% Underperform Votes21431.24% Autolus TherapeuticsOutperform Votes23168.34% Underperform Votes10731.66% Do analysts rate DNLI or AUTL? Denali Therapeutics presently has a consensus target price of $33.71, suggesting a potential upside of 125.82%. Autolus Therapeutics has a consensus target price of $9.32, suggesting a potential upside of 333.49%. Given Autolus Therapeutics' higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than Denali Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Denali Therapeutics 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 2 Strong Buy rating(s) 3.06Autolus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryDenali Therapeutics beats Autolus Therapeutics on 11 of the 18 factors compared between the two stocks. Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AUTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AUTL vs. The Competition Export to ExcelMetricAutolus TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$596.16M$3.12B$5.61B$8.62BDividend YieldN/A1.56%5.28%4.17%P/E Ratio-1.7832.9027.1719.96Price / Sales63.50466.20410.96157.63Price / CashN/A168.6838.2534.64Price / Book3.363.427.064.69Net Income-$208.38M-$72.35M$3.23B$248.14M7 Day Performance-8.12%3.01%0.77%0.95%1 Month Performance69.29%20.80%9.67%5.74%1 Year Performance-52.54%-17.10%32.02%14.73% Autolus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AUTLAutolus Therapeutics2.6074 of 5 stars$2.15-4.0%$9.32+333.5%-50.5%$596.16M$9.01M-1.78330Analyst ForecastDNLIDenali Therapeutics4.3529 of 5 stars$13.96+5.4%$33.71+141.5%-30.7%$2.03B$330.53M-5.06430Positive NewsAnalyst RevisionHigh Trading VolumeCGONCG Oncology2.5376 of 5 stars$26.59+3.8%$58.22+119.0%-25.4%$2.03B$662K-17.6161Positive NewsAnalyst RevisionVERAVera Therapeutics2.9034 of 5 stars$31.74+67.5%$65.00+104.8%-40.7%$2.02BN/A-12.1640Short Interest ↑Analyst RevisionHigh Trading VolumeGMTXGemini TherapeuticsN/A$46.68-0.4%N/A+30.9%$2.02BN/A-46.6830High Trading VolumeIMCRImmunocore3.0612 of 5 stars$38.65+5.6%$58.89+52.4%-12.1%$1.94B$333.58M-40.68320Positive NewsAnalyst RevisionHigh Trading VolumeGLPGGalapagos0.3789 of 5 stars$29.20+1.5%$25.33-13.2%+10.8%$1.92B$288.19M0.001,310AGIOAgios Pharmaceuticals4.1296 of 5 stars$32.63+1.7%$56.00+71.6%-28.1%$1.89B$37.04M2.88390Analyst RevisionTWSTTwist Bioscience4.2313 of 5 stars$31.07+6.0%$50.40+62.2%-35.9%$1.86B$347.68M-9.19990IDYAIDEAYA Biosciences4.0165 of 5 stars$21.22+6.7%$54.27+155.8%-43.5%$1.86B$7M-6.4380Positive NewsAnalyst RevisionTARSTarsus Pharmaceuticals2.2253 of 5 stars$43.85+2.1%$66.67+52.0%+25.1%$1.84B$233.67M-11.5150Positive News Related Companies and Tools Related Companies Denali Therapeutics Competitors CG Oncology Competitors Vera Therapeutics Competitors Gemini Therapeutics Competitors Immunocore Competitors Galapagos Competitors Agios Pharmaceuticals Competitors Twist Bioscience Competitors IDEAYA Biosciences Competitors Tarsus Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AUTL) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AUTL Stock Free AUTL Stock Alerts